NCT05029102 2024-02-12
TAS-102 and Anlotinib in ≥3 Lines mGC
Zhejiang University
Phase 2 Unknown
Clinical Trials
4 trialsNCT05385900 2022-05-23
ICTCPTLAGC
Xijing Hospital
Phase NA Unknown
NCT04777162 2021-03-04
Tislelizumab Plus Anlotinib for Immunotherapy Resistant Gastrointestinal Cancer
Peking University
Phase 2 Unknown
NCT02461407 2017-12-29
Study of Anlotinib in Patients With Gastric Cancer(ALTER0503)
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2/3 Unknown